EUVIMEDEUVIMED entdecken
Crossref

Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer

Adchata Konsue, Thomanai Lamtha, Duangkamol Gleeson, Donald J L Jones, Robert G Britton, James D Pickering, Kiattawee Choowongkomon, M Paul Gleeson

Bioorganic & Medicinal Chemistry · 2024

DOI: 10.1016/j.bmc.2024.117906 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2024. Verfasst von Adchata Konsue und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, School of Engineering, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand. Hauptthemen laut MEDLINE: ErbB Receptors, Protein Kinase Inhibitors, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 90 Literaturangaben. Gefördert von: King Mongkut's Institute of Technology Ladkrabang, National Research Council of Thailand.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Epidermal growth factor receptor (EGFR) kinase has been implicated in the uncontrolled cell growth associated with non-small cell lung cancer (NSCLC). This has prompted the development of 3 generations of EGFR inhibitors over the last 2 decades due to the rapid development of drug resistance issues caused by clinical mutations, including T790M, L858R and the double mutant T790M & L858R. In this work we report the design, preparation and biological assessment of new irreversible 2,4-diaminopyrimidine-based inhibitors of EGFR kinase. Twenty new compounds have been prepared and evaluated which incorporate a range of electrophilic moieties. These include acrylamide, 2-chloroacetamide and (2E)-3-phenylprop-2-enamide, to allow reaction with residue Cys797. In addition, more polar groups have been incorporated to provide a better balance of physical properties than clinical candidate Rociletinib. Inhibitory activities against EGFR wildtype (WT) and EGFR T790M & L858R have been evaluated along with cytotoxicity against EGFR-overexpressing (A549, A431) and normal cell lines (HepG2). Selectivity against JAK3 kinase as well as physicochemical properties determination (logD7.4 and phosphate buffer solubility) have been used to profile the compounds. We have identified 20, 21 and 23 as potent mutant EGFR inhibitors (≤20 nM), with comparable or better selectivity over WT EGFR, and lower activity at JAK3, than Osimertinib or Rociletinib. Compounds 21 displayed the best combination of EGFR mutant activity, JAK3 selectivity, cellular activity and physicochemical properties. Finally, kinetic studies on 21 were performed, confirming a covalent mechanism of action at EGFR.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ErbB ReceptorsProtein Kinase InhibitorsCarcinoma, Non-Small-Cell LungLung NeoplasmsPyrimidinesDrug DesignAntineoplastic AgentsCell ProliferationHumansStructure-Activity RelationshipDrug Screening Assays, AntitumorMolecular StructureDose-Response Relationship, DrugCell Line, TumorAcrylamides

Stichwörter der Autor:innen

Covalent inhibitorsEGFR kinaseMolecular modellingPyrimidine analoguesQM simulationsSolubility

Substanzen

ErbB ReceptorsProtein Kinase InhibitorsEGFR protein, humanPyrimidinesAntineoplastic AgentsrociletinibAcrylamides

Autor:innen und Institutionen

  • Department of Biomedical Engineering, School of Engineering, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand.
  • Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok 10900, Thailand.
  • Department of Chemistry & Applied Computational Chemistry Research Unit, School of Science, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand.
  • Leicester Cancer Research Centre, University of Leicester, Leicester LE1 7RH, United Kingdom.
  • School of Chemistry, University of Leicester, Leicester LE1 7RH, United Kingdom.
  • Department of Biomedical Engineering, School of Engineering, King Mongkut's Institute of Technology Ladkrabang, Bangkok 10520, Thailand. Electronic address: paul.gl@kmitl.ac.th.

Förderung

  • King Mongkut's Institute of Technology Ladkrabang
  • National Research Council of Thailand

Zitieren

APA

Konsue, A., Lamtha, T., Gleeson, D., Jones, D. J. L., Britton, R. G., Pickering, J. D., Choowongkomon, K., & Gleeson, M. P. (2024). Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer. Bioorganic & Medicinal Chemistry. https://doi.org/10.1016/j.bmc.2024.117906

Vancouver

Konsue A, Lamtha T, Gleeson D, Jones DJL, Britton RG, Pickering JD, et al. Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer. Bioorganic & Medicinal Chemistry. 2024. doi:10.1016/j.bmc.2024.117906

BibTeX
@article{Konsue2024,
  author = {Konsue, Adchata and Lamtha, Thomanai and Gleeson, Duangkamol and Jones, Donald J L and Britton, Robert G and Pickering, James D and Choowongkomon, Kiattawee and Gleeson, M Paul},
  title = {Design, preparation and biological evaluation of new Rociletinib-inspired analogs as irreversible EGFR inhibitors to treat non-small-cell-lung cancer},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2024},
  doi = {10.1016/j.bmc.2024.117906}
}
Kostenlos starten →